Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
QCOM$155.37-17.82(-10.29%)Qualcomm Q4: This Dip Is Not The One To Buy Yet7:45:04 AM ETAXP$337.55+4.93(+1.48%)American Express vs. PayPal: Which Financial Stock Is a Better Buy for 2027?7:45:01 AM ETSPCX$132.11-3.81(-2.80%)Stack Capital Group Inc. Reports Q3-2026 Financial Results7:45:00 AM ETCOP$139.00+2.06(+1.50%)BUZZ-ConocoPhillips rises on Q3 profit beat7:40:48 AM ETTGT$165.25+2.20(+1.35%)Target Looks More Attractive Than You'd Think7:31:07 AM ETCOP$139.00+2.06(+1.50%)UPDATE 2-ConocoPhillips beats estimates on higher oil prices, raises dividend7:30:23 AM ETCOP$139.00+2.06(+1.50%)ConocoPhillips Q3 profit beats on higher prices, hikes dividend7:26:13 AM ETMETA$636.50+6.50(+1.03%)UPDATE 2-Meta sells first bonds in euros, raises €9 billion7:25:25 AM ETDTE$137.45-0.06(-0.04%)UPDATE 1-DTE Energy to sell its non-utility business for about $3 billion7:23:30 AM ETAAPL$353.13+3.62(+1.04%)Jim Cramer's Surprise Midterm Winner: Apple, Because Fewer Data Centers Could Mean Cheaper Memory7:19:09 AM ETTSLA$376.32-8.87(-2.30%)Ferrari vs. Tesla: Can the Luce Outsell the Roadster?7:18:00 AM ETMU$755.48-39.98(-5.03%)Could Buying Micron Stock Today Help Set You Up for Life?7:17:00 AM ETMSFT$557.00+1.20(+0.22%)Microsoft Is Executing an Irreproducible Balance-Sheet-Backed Infrastructure Pre-Sale at Scale7:15:58 AM ETAAPL$353.13+3.62(+1.04%)Apple Vs. Tesla: Low CapEx Only Matters if Non-Cyclical Cash Flows Come With It7:15:57 AM ETIREN$20.58-1.12(-5.16%)IREN is Only Fit for a Specific Investor Currently7:15:22 AM ETCOP$139.00+2.06(+1.50%)BRIEF-Conocophillips Q3 Adjusted EPS USD 3.27 Vs. IBES Estimate USD 2.977:13:20 AM ETMU$755.48-39.98(-5.03%)Micron Just Closed Below $800 for the First Time Since July7:12:48 AM ETAAPL$353.13+3.62(+1.04%)Amazon, Apple, FTAI Aviation And A Basic Material Stock: CNBC's ‘Final Trades'7:12:08 AM ETCOP$139.00+2.06(+1.50%)ConocoPhillips beats profit estimates, boosts quarterly dividend7:11:13 AM ETCRWD$234.12-6.88(-2.85%)Too Late to Buy CrowdStrike Stock? Here's the 1 Thing to Watch.7:10:00 AM ETGOOG$290.19+2.89(+1.01%)These 6 Stocks Make Up a Big Share of the S&P 5007:09:00 AM ETCOP$139.00+2.06(+1.50%)UPDATE 1-ConocoPhillips beats profit estimates, boosts quarterly dividend7:07:07 AM ETLLY$1,433.00+14.86(+1.05%)Iconic California Brand, French Florist, Celebrates Grand Opening of First Indiana Location7:07:00 AM ETCVS$80.54+0.55(+0.69%)ProjectLeo, the First Private AI Health Platform to Declare Independence From Big Tech7:04:00 AM ET

MDCX · NASDAQ

Medicus Pharma Ltd.

$1.99 +0.18 (+9.94%)

Company overview

Medicus Pharma Ltd. is a biotech and life sciences company focused on accelerating the clinical development of novel and disruptive therapeutic assets, with an emphasis on non-invasive treatments for skin cancer.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$2.9M
Employees
12
Headquarters
W. Conshohocken
Website
medicuspharma.com
CEO
Raza Bokhari
Listed
November 15, 2024
P/E
-0.90
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
$0.00
Operating income
-$35.5M
EBITDA
-$35.5M
Net income
-$36.9M
EPS
-$2.20
Total assets
$7.4M
Total debt
$169,624
Earnings yield
-110.55%

Price chart

-0.101.142.393.634.87
MDCX 1D NASDAQ O2.12H2.16L1.71C1.81-0.22 (-10.84%)Vol109.89K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
MDCXMedicus Pharma Ltd. Press release Medicus Pharma to Present at BIO-Europe 2026 GlobeNewswire
MDCXMedicus Pharma Ltd. Press release Medicus Pharma to Host Third Quarter 2026 Financial Performance and Business Update Call on November 9, 2026 GlobeNewswire
MDCXMedicus Pharma Ltd. Press release Medicus Pharma Announces Proposed SkinJect® Business Combination and Concurrent Financing GlobeNewswire
MDCXMedicus Pharma Ltd. Press release Medicus Pharma to Present at BioFuture and Global Biotechnology Summit GlobeNewswire
MDCXMedicus Pharma Ltd. Press release Medicus Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement GlobeNewswire
MDCXMedicus Pharma Ltd. Stock news Medicus Pharma targets partnerships and clinical milestones as oncology pipeline advances Proactive Investors
MDCXMedicus Pharma Ltd. Press release Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value GlobeNewswire
MDCXMedicus Pharma Ltd. Stock news Medicus Pharma files streamlined Phase 2b/3 prostate cancer trial design with FDA Proactive Investors
MDCXMedicus Pharma Ltd. Press release Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer GlobeNewswire
MDCXMedicus Pharma Ltd. Stock news Medicus Pharma to focus SkinJect development exclusively on Gorlin syndrome patients Proactive Investors
MDCXMedicus Pharma Ltd. Press release Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment GlobeNewswire
MDCXMedicus Pharma Ltd. Stock news Medicus Pharma CEO on SkinJect and Pfizer partnership – ICYMI Proactive Investors
MDCXMedicus Pharma Ltd. Stock news Medicus Pharma reports positive Phase 2 data for SkinJect in skin cancer treatment Proactive Investors
MDCXMedicus Pharma Ltd. Press release Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose GlobeNewswire
MDCXMedicus Pharma Ltd. Press release Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® GlobeNewswire
MDCXMedicus Pharma Ltd. Stock news Medicus Pharma reorients around new cancer drug candidate, sharpens focus for other programs Proactive Investors
MDCXMedicus Pharma Ltd. Press release Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company GlobeNewswire
MDCXMedicus Pharma Ltd. Stock news Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion Benzinga
MDCXMedicus Pharma Ltd. Stock news Medicus Pharma advances pipeline during Q2 with key milestones Proactive Investors
MDCXMedicus Pharma Ltd. Press release Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update Accesswire
See more
FAQ

Questions about Medicus Pharma Ltd.

What does Medicus Pharma Ltd. do?
Medicus Pharma Ltd. is a biotech and life sciences company focused on accelerating the clinical development of novel and disruptive therapeutic assets, with an emphasis on non-invasive treatments for skin cancer.
What is MDCX's market cap?
Medicus Pharma Ltd. (MDCX) is a listed stock with a live quote. The latest market cap on this page is $2.9M.
Where is Medicus Pharma Ltd. headquartered?
Medicus Pharma Ltd. is headquartered in W. Conshohocken.
How do I get MDCX news from the API?
Call GET /v1/news?tickers=MDCX. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does MDCX news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for MDCX, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the MDCX price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs